Suppr超能文献

维生素 D 缺乏、补充和检测:新西兰是否做对了?

Vitamin D deficiency, supplementation and testing: have we got it right in New Zealand?

机构信息

MBChB, PhD, Associate Professor of Medicine, Department of Medicine, University of Auckland, New Zealand; Endocrinologist, Auckland District Health Board, New Zealand.

MD, Clinical Chair in Health Services Research, Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland.

出版信息

N Z Med J. 2021 Sep 3;134(1541):86-95.

Abstract

BACKGROUND

Severe prolonged vitamin D deficiency can cause rickets or osteomalacia. Both can be prevented by sunshine exposure or vitamin D supplementation. Although New Zealand guidance does not recommend vitamin D supplementation for the general population, it can be considered for individuals at risk of vitamin D deficiency. Routine measurement of 25-hydroxyvitamin D (25OHD) is also considered unnecessary.

METHODS

We investigated the rates of vitamin D supplementation, rickets and osteomalacia in New Zealand, and of 25OHD results in Auckland, over the last two decades.

RESULTS

Vitamin D prescriptions increased 14-fold, from 86,295/year to 1,215,507/year, between 2003 and 2019, with medication costs alone in 2019 being >$1 million. Despite these changes, the annual prevalence of hospital admissions for rickets, osteomalacia and unspecified vitamin D deficiency remained low and stable (10-20/year). 25OHD concentrations increased between 2002 and 2003 and between 2009 and 2019, and in the later time-period, 25OHD tests mainly identified individuals without vitamin D deficiency (40-50% >75nmol/L, 65-70% >50nmol/L and only 7-12.5% <25nmol/L).

CONCLUSIONS

Osteomalacia and rickets persist at low rates despite widespread, increasingly costly vitamin D supplementation and testing, which largely identifies individuals without vitamin D deficiency. These results suggest that vitamin D guidance and practice in New Zealand should change.

摘要

背景

严重且长期的维生素 D 缺乏可导致佝偻病或骨软化症。通过阳光照射或维生素 D 补充均可预防这两种疾病。尽管新西兰指南不建议为普通人群补充维生素 D,但对于有维生素 D 缺乏风险的个体可以考虑补充。常规测量 25-羟维生素 D(25OHD)也被认为是不必要的。

方法

我们调查了过去二十年新西兰维生素 D 补充剂、佝偻病和骨软化症的使用情况,以及奥克兰 25OHD 检测结果。

结果

2003 年至 2019 年,维生素 D 处方增加了 14 倍,从每年 86,295 张增加到 1,215,507 张,仅 2019 年的药物费用就超过 100 万新西兰元。尽管发生了这些变化,但佝偻病、骨软化症和未明确维生素 D 缺乏的住院率仍然较低且稳定(每年 10-20 例)。25OHD 浓度在 2002 年至 2003 年以及 2009 年至 2019 年间有所增加,在后一时期,25OHD 检测主要确定了没有维生素 D 缺乏的个体(40-50%>75nmol/L,65-70%>50nmol/L,仅有 7-12.5%<25nmol/L)。

结论

尽管广泛且成本不断增加的维生素 D 补充和检测,但佝偻病和骨软化症的发生率仍然较低,且主要发现了没有维生素 D 缺乏的个体。这些结果表明,新西兰的维生素 D 指南和实践应该改变。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验